MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Xenomics, Inc. (PINKSHEETS: XNOM), a developer of non-invasive next-generation molecular diagnostics, announced today that it will begin offering a gender prediction test as a service to expectant mothers who are interested in learning the gender of their baby as early as the 7th week of their pregnancy, much earlier than the availability of reliable ultrasound results. The Xenomics test is based on the detection of male-specific Y chromosome sequences in maternal urine using the Company’s proprietary technology for the analysis of Transrenal DNA (Tr-DNA). The service is designed and offered solely for an expectant mother’s information and does not provide any medical diagnoses or guidance. Visitors to the Company’s website www.xenogentest.com can order a test kit containing materials and instructions for the collection of a urine sample and the submission of a sample to the Company for analysis. The Company will report the predicted gender of their baby, as indicated by its test, within 5 to 8 days of sample submission.
